Circulation of rare events in the liquid biopsy for early detection of lung mass lesions.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS
ACS Applied Bio Materials Pub Date : 2024-10-01 Epub Date: 2024-09-04 DOI:10.1111/1759-7714.15429
Karen Resnick, Anya Shah, Jeremy Mason, Peter Kuhn, Jorge Nieva, Stephanie N Shishido
{"title":"Circulation of rare events in the liquid biopsy for early detection of lung mass lesions.","authors":"Karen Resnick, Anya Shah, Jeremy Mason, Peter Kuhn, Jorge Nieva, Stephanie N Shishido","doi":"10.1111/1759-7714.15429","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Lung cancer screening with low-dose computed tomography (CT) scans (LDCT) has reduced mortality for patients with high-risk smoking histories, but it has significant limitations: LDCT screening implementation remains low, high rates of false-positive scans, and current guidelines exclude those without smoking histories. We sought to explore the utility of liquid biopsy (LBx) in early cancer screening and diagnosis of lung cancer.</p><p><strong>Methods: </strong>Using the high-definition single-cell assay workflow, we analyzed 99 peripheral blood samples from three cohorts: normal donors (NDs) with no known pathology (n = 50), screening CT patients (n = 25) with Lung-RADS score of 1-2, and biopsy (BX) patients (n = 24) with abnormal CT scans requiring tissue biopsy.</p><p><strong>Results: </strong>For CT and BX patients, demographic information was roughly equivalent; however, average pack-years smoked differed. A total of 14 (58%) BX patients were diagnosed with primary lung cancer (BX+). The comparison of the rare event enumerations among the cohorts revealed a greater incidence of total events, rare cells, and oncosomes, as well as specific cellular phenotypes in the CT and BX cohorts compared with the ND cohort. LBx analytes were also significantly elevated in the BX compared with the CT samples, but there was no difference between BX+ and BX- samples.</p><p><strong>Conclusions: </strong>The data support the utility of the LBx in distinguishing patients with an alveolar lesion from those without, providing a potential avenue for prescreening before LDCT.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471425/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1759-7714.15429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Lung cancer screening with low-dose computed tomography (CT) scans (LDCT) has reduced mortality for patients with high-risk smoking histories, but it has significant limitations: LDCT screening implementation remains low, high rates of false-positive scans, and current guidelines exclude those without smoking histories. We sought to explore the utility of liquid biopsy (LBx) in early cancer screening and diagnosis of lung cancer.

Methods: Using the high-definition single-cell assay workflow, we analyzed 99 peripheral blood samples from three cohorts: normal donors (NDs) with no known pathology (n = 50), screening CT patients (n = 25) with Lung-RADS score of 1-2, and biopsy (BX) patients (n = 24) with abnormal CT scans requiring tissue biopsy.

Results: For CT and BX patients, demographic information was roughly equivalent; however, average pack-years smoked differed. A total of 14 (58%) BX patients were diagnosed with primary lung cancer (BX+). The comparison of the rare event enumerations among the cohorts revealed a greater incidence of total events, rare cells, and oncosomes, as well as specific cellular phenotypes in the CT and BX cohorts compared with the ND cohort. LBx analytes were also significantly elevated in the BX compared with the CT samples, but there was no difference between BX+ and BX- samples.

Conclusions: The data support the utility of the LBx in distinguishing patients with an alveolar lesion from those without, providing a potential avenue for prescreening before LDCT.

用于早期检测肺部肿块病变的液体活检中罕见事件的循环。
背景:使用低剂量计算机断层扫描(CT)进行肺癌筛查(LDCT)可降低有高危吸烟史患者的死亡率,但也有很大的局限性:低剂量计算机断层扫描筛查的实施率仍然很低,扫描的假阳性率很高,而且现行指南将无吸烟史的患者排除在外。我们试图探索液体活检(LBx)在早期癌症筛查和肺癌诊断中的作用:使用高清单细胞检测工作流程,我们分析了来自三个队列的 99 份外周血样本:未发现病变的正常供血者(NDs)(n = 50)、肺-RADS 评分为 1-2 分的 CT 筛查患者(n = 25)和 CT 扫描异常需要组织活检的活检(BX)患者(n = 24):CT 和 BX 患者的人口统计学信息大致相同,但平均吸烟年数不同。共有 14 名(58%)BX 患者被诊断为原发性肺癌(BX+)。通过比较各组群的罕见事件计数,发现与 ND 组群相比,CT 和 BX 组群的总事件、罕见细胞、oncosomes 以及特定细胞表型的发生率更高。与 CT 样本相比,BX 样本中的枸橼酸分析物也明显升高,但 BX+ 和 BX- 样本之间没有差异:这些数据支持 LBx 在区分肺泡病变和非肺泡病变患者方面的作用,为 LDCT 前的预检提供了潜在的途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信